Swedish Orphan Biovitrum AB (LTS:0MTD) EPS (Basic): kr2.65 (TTM As of Mar. 2026)


LTS:0MTD Swedish Orphan Biovitrum AB LTS:0MTD
86 GF Score
Price kr462.60
GF Value kr343.25
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Swedish Orphan Biovitrum AB EPS (Basic)?

Swedish Orphan Biovitrum AB LTS:0MTD +3.70% 86 EPS (Basic) is kr2.65 as of Mar. 2026. GuruFocus rates LTS:0MTD with a GF Score™ of 86/100 and a GF Value™ of kr343.25 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Swedish Orphan Biovitrum AB's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was kr3.81. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was kr2.65.

Swedish Orphan Biovitrum AB's EPS (Diluted) for the three months ended in Mar. 2026 was kr3.77. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr2.54.

Swedish Orphan Biovitrum AB's EPS without NRI for the three months ended in Mar. 2026 was kr4.07. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 18.13.

During the past 12 months, Swedish Orphan Biovitrum AB's average EPS without NRIGrowth Rate was 55.80% per year. During the past 3 years, the average EPS without NRI Growth Rate was 18.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was 11.40% per year. During the past 10 years, the average EPS without NRI Growth Rate was 30.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Swedish Orphan Biovitrum AB's highest 3-Year average EPS without NRI Growth Rate was 253.40% per year. The lowest was -46.10% per year. And the median was -1.05% per year.

Swedish Orphan Biovitrum AB  (LTS:0MTD) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Swedish Orphan Biovitrum AB EPS (Basic) Related Terms

Swedish Orphan Biovitrum AB EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Swedish Orphan Biovitrum AB's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Swedish Orphan Biovitrum AB EPS (Basic) Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.67 8.52 7.47 11.37 1.39

Swedish Orphan Biovitrum AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.55 1.85 -8.40 5.39 3.81
LTS:0MTD
86GF Score
Swedish Orphan Biovitrum AB LTS:0MTD
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Swedish Orphan Biovitrum AB EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Swedish Orphan Biovitrum AB's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(478-0)/344.299
=1.39

Swedish Orphan Biovitrum AB's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(1318-0)/345.763
=3.81

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr2.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of kr2.65 mean?
Swedish Orphan Biovitrum AB (LTS:0MTD) has a EPS (Basic) of kr2.65 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Swedish Orphan Biovitrum AB and its competitors.
Is Swedish Orphan Biovitrum AB's EPS (Basic) too high?
Swedish Orphan Biovitrum AB's current EPS (Basic) is kr2.65. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 86/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's EPS (Basic) compare to ZTS?
Swedish Orphan Biovitrum AB's EPS (Basic) of kr2.65 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Swedish Orphan Biovitrum AB and its competitors. Swedish Orphan Biovitrum AB's current EPS (Basic) is kr2.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (LTS:0MTD) is currently considered Significantly Overvalued. The stock's GF Value™ is kr343.25, compared to a current price of kr462.60 — trading 34.8% above its estimated fair value. The current EPS (Basic) is kr2.65. Swedish Orphan Biovitrum AB's overall GF Score™ is 86/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (LTS:0MTD), the current EPS (Basic) is kr2.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Swedish Orphan Biovitrum AB (LTS:0MTD) Overvalued in 2026?

Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued. The current stock price of kr462.60 is trading 34.8% above its estimated GF Value™ of kr343.25. GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.

Key valuation signals for LTS:0MTD:

  • EPS (Basic): kr2.65
  • GF Value™: kr343.25 vs. price of kr462.60 (34.8% above fair value)
  • GF Score™: 86/100 with 7 warning signs

No single metric tells the full story. See the LTS:0MTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Swedish Orphan Biovitrum AB Business Description

Address Norra Stationsgatan 93A, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
86GF Score

Get the complete analysis for LTS:0MTD

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr462.60
Price
kr343.25
GF Value